CT-Guided Stereotactic Radiosurgery Planning for Brain Tumors in Dogs

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• CT-guided stereotactic radiosurgery (SRS) planning for canine brain tumors necessitates precise patient positioning and immobilization, typically using a rigid headframe or frameless mask system, to ensure millimeter-scale geometric accuracy between imaging and treatment delivery.
• Intravenous contrast administration is mandatory during CT acquisition to delineate the contrast-enhancing gross tumor volume (GTV), and coregistration with MRI is standard practice when available to refine tumor margins due to MRI's superior soft tissue contrast.
• The clinical target volume (CTV) for SRS is typically identical to the GTV, as a geographic margin is generally not added due to the steep dose gradient and single-fraction delivery, distinguishing it from fractionated radiation therapy.
• Critical structures such as the brainstem, optic chiasm, optic nerves, inner ears, and pituitary gland must be meticulously contoured on the planning CT, often with MRI fusion, to ensure their dose remains within established tolerance thresholds.
• Quality assurance is paramount, involving verification of stereotactic localizer registration, isocenter coordinates, and frame/mask stability before treatment delivery to mitigate motion artifact and ensure accurate dose targeting.
• Recognized complications include radiation necrosis and tumor progression, with early detection relying on serial contrast-enhanced MRI, and common planning errors involve inadequate MRI fusion, misregistration of stereotactic localization, and contouring peritumoral edema as tumor.

Stereotactic radiosurgery (SRS) delivers a single, highly conformal dose of radiation to an intracranial target using multiple non-coplanar, stereotactically focused beams. The technique exploits a steep dose gradient to ablate tumor tissue while minimizing exposure to adjacent normal brain. Computed tomography with a stereotactic localizer secured to the skull generates a three-dimensional image of the target and provides accurate spatial coordinates for computerized treatment planning and delivery, as described in early veterinary application of headframe-based systems (Lester et al., 2001). This article addresses the CT imaging components of SRS planning for canine brain tumors: image acquisition, patient positioning, target delineation, and quality assurance. It serves the practicing veterinarian who refers patients for radiosurgery or participates in the planning process, and it answers the procedural question of how CT data are obtained and translated into a treatment plan. Treatment delivery mechanics and radiobiology are outside the scope of this discussion.

The clinical rationale for SRS in dogs rests on the observation that fractionated radiation protocols require multiple anesthetic episodes over several weeks, whereas radiosurgery achieves tumor control in a single session. Reported outcomes in dogs include substantial tumor volume reduction and improved survival, with treated dogs surviving beyond one year more likely to die from unrelated causes than from their primary brain tumor (Zwingenberger et al., 2016). The planning process determines whether these outcomes are achievable, because geometric accuracy at the millimeter scale governs both tumor coverage and normal tissue sparing.

At a Glance

Principles of Stereotactic Localization

Stereotactic radiosurgery depends on a rigid spatial relationship between the patient's skull, an imaging localizer, and the treatment delivery system. In frame-based systems, a headframe is secured to the skull under anesthesia before imaging. The frame carries a localizer box with fiducial markers visible on CT, and the spatial coordinates of any intracranial point can be derived from the fiducial positions in the image volume (Lester et al., 2001). Frameless systems use a thermoplastic mask or bite-block registration that is tracked optically during both imaging and treatment. The fundamental requirement is identical geometry between the planning CT and the delivery session, any shift invalidates the coordinate transformation.

The accuracy of the entire procedure depends on the CT dataset. Voxel dimensions must be isotropic in the axial plane, with slice thickness sufficiently small to resolve the fiducial markers and the tumor margin without partial volume averaging. Most veterinary planning protocols use 1 to 1.5 mm contiguous slices through the entire calvarium. The field of view should include the full circumference of the head with the localizer frame or mask fiducials visible in every slice. Motion artifact is the most common cause of planning failure, because it degrades fiducial registration and blurs the tumor boundary. A stable anesthetic plane, often with neuromuscular blockade and controlled ventilation, is required for the duration of the scan.

Image Acquisition Protocol

The planning CT is performed with the patient in the same position that will be used for treatment. For frame-based systems, the frame is applied before imaging and remains in place until after delivery. For frameless systems, the mask is molded and the patient is scanned wearing it. The head is positioned sternum down with the hard palate perpendicular to the table, which standardizes the relationship between the skull base and the imaging plane. This position also facilitates reproducible setup for the linear accelerator or gamma unit.

Intravenous contrast administration is mandatory for tumor delineation. Most canine brain tumors, particularly meningiomas, show contrast enhancement that defines the gross tumor volume. Acquisition should begin after a short delay to allow contrast distribution into the tumor interstitium. The scan volume extends from the cranial vault through the foramen magnum to include the entire brain and any lesion extension into the caudal fossa. Bone algorithm reconstructions are useful for identifying calvarial involvement, while soft tissue algorithms are used for tumor and normal brain visualization.

Target Delineation and Image Fusion

Accurate target delineation is the most consequential step in SRS planning. The gross tumor volume is defined as the contrast-enhancing lesion on T1-weighted MRI and the corresponding enhancing region on CT. Magnetic resonance imaging provides superior soft tissue contrast for identifying tumor margins, particularly at the brain-tumor interface where CT enhancement may be ambiguous. Coregistration of MRI and CT using registration software is therefore standard practice when both modalities are available, a technique also used in experimental models to define tumor boundaries for radiosurgical targeting (Kumar et al., 2012). The CT dataset provides the spatial reference for treatment planning, while the MRI informs the biological target.

The clinical target volume for SRS is typically identical to the gross tumor volume, because the steep dose gradient and single-fraction delivery do not accommodate a geographic margin without unacceptable normal tissue toxicity. This distinguishes SRS from fractionated radiation therapy, where a margin accounts for setup error and microscopic disease extension. The planning target volume is determined by the mechanical accuracy of the delivery system and the precision of patient immobilization. For frame-based systems, this margin may be 1 mm or less.

Critical Structure Delineation

Normal tissue tolerance is the limiting factor in single-fraction radiosurgery. The brainstem, optic chiasm, optic nerves, and pituitary gland must be contoured on the planning CT, with MRI fusion used to refine their boundaries when necessary. The dose to these structures is constrained by published tolerance thresholds, and the treatment plan is optimized to keep the dose gradient steep enough that critical structures fall outside the high-dose region. The inner ears and cochleae are also contoured when the target lies in the caudal fossa, because hearing loss is a recognized complication of radiosurgery in this region.

The relationship between target volume and critical structure proximity determines whether SRS is feasible. A tumor that abuts or invades the optic chiasm may require dose reduction to the tumor margin, with a corresponding decrease in tumor control probability. This trade-off is discussed with the owner before treatment, and the planning process quantifies the expected dose to each structure so that the decision is informed by data instead of assumption.

Quality Assurance in the Planning Pathway

Quality assurance begins before image acquisition and continues through plan approval. The stereotactic localizer or mask registration is verified by comparing fiducial positions in the planning CT with expected values. The isocenter coordinates are calculated from the fiducial geometry and checked against the treatment plan. A second verification, often using orthogonal radiographs or a second CT, confirms that the planned isocenter corresponds to the intended intracranial location. Any discrepancy between the imaging coordinate system and the delivery coordinate system requires repetition of the planning scan.

The American College of Veterinary Radiology maintains professional standards for diagnostic imaging practice and radiation safety that apply to the personnel and equipment used in radiosurgery planning (ACVR resources). These standards address image quality, equipment calibration, and the qualifications of personnel who perform and interpret the planning studies. Adherence to these standards is a prerequisite for the geometric accuracy that radiosurgery demands.

Patient Selection and Pretreatment Assessment

Stereotactic radiosurgery planning begins before image acquisition. The decision to pursue SRS depends on tumor type, size, location, and neurologic status. Meningiomas and other extra-axial masses are favorable targets because their well-defined margins permit accurate contouring and steep dose gradients. Intra-axial gliomas present greater challenges due to infiltrative borders that may not correspond to contrast-enhancing margins on CT.

Tumor volume influences feasibility. Most veterinary linear accelerator systems can treat targets up to approximately 15 to 20 cm³ with acceptable normal tissue tolerance, though published experience includes a range of tumor sizes. Larger lesions require either dose reduction, fractionation, or alternative approaches. The institutional report on stereotactic headframe radiosurgery in dogs describes treatment of three dogs with tumors of varying histologies, demonstrating that meningiomas and oligodendrogliomas can be managed with single-fraction delivery.

Pretreatment assessment should include:

• Complete neurologic examination with documentation of lateralizing signs
• MRI with and without contrast, ideally performed before the planning CT
• Coagulation profile if biopsy is contemplated
• Assessment of concurrent disease that may affect anesthetic risk
• Owner discussion of expected response, complications, and follow-up schedule

The prospective evaluation of canine brain tumor response to SRS and SRT documented significant tumor volume reduction at three months after treatment, with mean volume decline of 0.826 cm³. Dogs surviving beyond one year were more likely to die from unrelated causes than from their brain tumor. These data support SRS as a reasonable first-line option for accessible, well-circumscribed tumors.

Anesthesia and Positioning for CT Simulation

General anesthesia is mandatory for CT simulation. The patient must remain motionless throughout acquisition, and the head must be reproducibly positioned relative to the stereotactic localizer. Most systems use a rigid headframe or bite-block immobilization device that attaches to the CT table.

Anesthetic considerations specific to brain tumor patients include:

• Avoidance of drugs that increase intracranial pressure
• Maintenance of normocapnia to prevent cerebral vasodilation
• Blood pressure support to preserve cerebral perfusion pressure
• Short-acting agents to facilitate rapid recovery and neurologic assessment

Positioning should reproduce the orientation used for treatment delivery. The head is typically positioned with the hard palate perpendicular to the table surface, though the exact orientation depends on the localizer design and treatment planning software. The ACVR professional resources provide specialty standards for imaging practice that include positioning and quality assurance expectations.

After positioning, a scout image confirms head alignment. The planning CT is then acquired using the protocol described in the Image Acquisition Protocol section of this article.

CT Acquisition Parameters for Planning

The planning CT must satisfy conflicting requirements: high spatial resolution for target delineation, low artifact from dental and osseous structures, and compatibility with the treatment planning system. Slice thickness of 1 to 1.5 mm is standard for brain SRS planning. Thicker slices degrade the accuracy of dose calculation and target localization, particularly for small tumors.

Key acquisition parameters include:

Contrast administration is essential for most brain tumors. The scan should be acquired during or immediately after contrast injection to capture the enhancement phase. Delayed imaging may be useful for tumors with slow contrast uptake, though this is uncommon in canine meningiomas.

Dental artifact from the caudal mandibular teeth can obscure the ventral brainstem and cerebellum. If the localizer permits, slight rostral traction on the mandible may reduce artifact. Alternatively, a dental acrylic bite block can separate the dental arches.

Target Volume Definition

The gross tumor volume (GTV) is defined on the contrast-enhanced CT. For meningiomas, the GTV corresponds to the contrast-enhancing mass with its dural tail if visible. For gliomas, the GTV is more difficult to define because tumor cells extend beyond the enhancing margin. The rodent glioma model study demonstrated that radiosurgery produces a direct cytotoxic response in glial neoplasms, with treated tumors showing hypocellularity and cellular edema, but the study also confirmed that tumor response varies with dose distribution.

The clinical target volume (CTV) accounts for microscopic extension. For meningiomas, a 1 to 2 mm margin is typically sufficient. For gliomas, margins of 3 to 5 mm may be used, though this increases normal tissue exposure. The planning target volume (PTV) adds a further margin for patient movement and positioning uncertainty. With rigid headframe immobilization, the PTV margin can be as small as 1 mm.

Image fusion with MRI improves target delineation. The rodent model of radiation necrosis used fused CT and MR images to identify tumor boundaries, and the authors noted that fusion allowed more accurate target definition than either modality alone. In clinical canine patients, T1-weighted post-contrast MRI fused to the planning CT is the standard approach for tumors with subtle CT enhancement.

Critical Structure Contouring

Normal tissue tolerance determines the acceptable dose distribution. Structures that must be contoured include:

• Brainstem
• Optic nerves and chiasm
• Eyes and lenses
• Cochleae
• Pituitary gland
• Normal brain parenchyma

The brainstem is the most important dose-limiting structure. Published veterinary experience with single-fraction radiosurgery is limited, but the porcine model of small volume radiosurgery demonstrated dose-dependent histologic changes, with necrotic lesions appearing in white matter at 60 Gy and in grey matter at 100 Gy. These doses exceed typical veterinary prescriptions, but the study illustrates that normal tissue response is both dose- and volume-dependent.

Contouring conventions should follow a consistent protocol. The brainstem is contoured from the rostral mesencephalon to the spinomedullary junction. The optic chiasm is identified on the fused MRI and contoured separately from the optic nerves. The eyes are contoured as whole globes, with the lens identified separately if the tumor is rostral.

Plan Evaluation and Documentation

The treatment planning system generates dose-volume histograms for each contoured structure. Plan evaluation should consider:

• PTV coverage: at least 95% of the PTV receives the prescription dose
• PTV homogeneity: maximum dose should not exceed 110 to 120% of prescription
• Brainstem maximum dose: should not exceed tolerance
• Optic apparatus maximum dose: should not exceed tolerance
• Conformality index: ratio of prescription isodose volume to PTV volume

Documentation should include the planning CT images, contour volumes, dose-volume histograms, and the final treatment plan. The AVMA practice resources emphasize the importance of complete medical records, including imaging studies and treatment plans, for continuity of care and medicolegal purposes.

The planning process concludes with a final verification of stereotactic coordinates. Most systems include a quality assurance step that compares the planned isocenter with the localizer-derived coordinates. This verification should be performed before the patient is removed from anesthesia, allowing immediate repositioning if a discrepancy is identified.

Structured Checklist for CT Simulation and Contouring

The following checklist summarizes the practical steps in SRS planning:

Pre-simulation

• Confirm tumor type and size on diagnostic MRI
• Confirm tumor is suitable for single-fraction treatment
• Review anesthetic risk and concurrent disease
• Obtain owner consent with realistic outcome expectations

Simulation

• Position patient in stereotactic localizer
• Confirm head alignment on scout image
• Acquire non-contrast planning CT
• Administer contrast and acquire post-contrast CT
• Verify image quality and absence of motion artifact
• Transfer images to treatment planning system

Contouring

• Fuse MRI to planning CT
• Contour GTV on contrast-enhanced images
• Add CTV and PTV margins according to tumor type
• Contour all critical structures
• Review contours on fused images

Plan evaluation

• Generate dose-volume histograms
• Verify PTV coverage and homogeneity
• Check critical structure doses
• Confirm stereotactic coordinates
• Document plan and obtain final approval

Equipment availability changes several steps. Facilities without MRI fusion capability must rely on CT alone for target delineation, which may underestimate tumor extent for gliomas. Facilities without rigid headframe immobilization must use larger PTV margins, which increases normal tissue dose. These limitations should be discussed with the owner before treatment is recommended.

Recognized Complications and Early Detection

The principal complications after CT-guided stereotactic radiosurgery planning for canine brain tumors fall into three categories: radiation necrosis, tumor progression, and technical failure of dose delivery. Radiation necrosis is the most consequential normal tissue effect. In experimental models, the threshold for necrosis depends on both dose and tissue type. A porcine study of small-volume radiosurgery demonstrated necrotic lesions in grey matter at 100 Gy and in white matter at 60 Gy, with vascular, neuronal, and glial changes occurring at lower doses. These findings underscore that white matter tracts are more vulnerable than grey matter, a consideration when planning dose constraints for the internal capsule, optic tracts, and brainstem.

Early detection of radiation necrosis relies on serial imaging. Contrast-enhanced MRI at three-month intervals is the standard surveillance approach, but differentiating necrosis from tumor recurrence remains a diagnostic challenge. A rodent model combining stereotactic radiosurgery with orthotopic glioblastoma implantation showed that fused CT and MR images can delineate the high-dose necrotic core from the viable peripheral tumor, and immunohistological confirmation with hematoxylin and eosin staining distinguished liquefaction necrosis from viable neoplastic tissue. In clinical canine patients, perfusion-weighted MRI and MR spectroscopy provide adjunctive discrimination, though neither modality is definitive. When imaging findings are equivocal, biopsy or close-interval reimaging is warranted.

Tumor progression despite adequate planning occurs when the target volume underestimates microscopic disease extension. Meningiomas and gliomas both show infiltrative margins that may not be visible on contrast-enhanced CT. The response of canine brain tumors to SRS and SRT includes significant reductions in tumor volume, blood flow, and blood volume at three and six months after treatment, and dogs surviving beyond one year are more likely to die from unrelated causes than from their primary brain tumor. However, early volume reduction does not guarantee durable control, and progressive contrast enhancement beyond six months should prompt investigation for recurrence instead of assuming treatment failure.

Common Planning Errors and Corrective Actions

Less experienced clinicians frequently make errors in target delineation and image fusion. The most common mistake is contouring the contrast-enhancing margin on CT alone without MRI fusion. CT provides spatial coordinates for treatment planning, but MRI offers superior soft tissue contrast for tumor boundary identification. The corrective action is to acquire a high-resolution T1-weighted post-contrast MRI sequence and fuse it to the planning CT using rigid registration software, then verify fusion accuracy at multiple anatomic landmarks.

A second frequent error is misregistration of the stereotactic localizer frame. The localizer fiducial markers must be visible on every axial slice used for planning, and any slice with obscured or distorted fiducials should be repeated. Frame movement between CT acquisition and treatment delivery invalidates the spatial coordinate system. Verification of frame position immediately before each imaging sequence and again before treatment is mandatory.

A third error involves contouring edema as tumor. Peritumoral T2 hyperintensity on MRI represents vasogenic edema, not neoplastic infiltration, and including it in the gross tumor volume unnecessarily enlarges the treatment field and increases normal tissue dose. The corrective action is to contour the contrast-enhancing lesion as the gross tumor volume and add a margin only according to the institutional protocol for the specific histologic tumor type.

Limitations of Current Evidence

The evidence base for CT-guided stereotactic radiosurgery planning in canine brain tumors rests on small case series and experimental models. The earliest reported canine series treated three dogs with meningiomas or oligodendroglioma using a linear accelerator and stereotactic headframe, with survivals of 227, 66, and 56 weeks. This demonstrates feasibility but provides no basis for comparative efficacy against fractionated radiation therapy. A prospective study of 34 dogs evaluated volume and perfusion responses but did not randomize between SRS and SRT, and the histologic diagnoses were not confirmed in all cases.

Expert opinion differs on several points. The optimal planning target volume margin remains contested, with some authorities advocating no margin for well-circumscribed meningiomas and others recommending a 1 to 2 mm margin to account for positioning uncertainty. The role of single-fraction SRS versus hypofractionated SRT for tumors adjacent to critical structures is also debated. Experimental glioma models show a direct cytotoxic response to radiosurgery with reduced tumor diameter and hypocellularity, but dose escalation beyond 40 Gy did not improve tumor response in one rat model. Whether this plateau effect applies to canine tumors is unknown.

Referral, Consultation, and Reporting

Referral to a veterinary radiation oncologist is indicated when the planning CT reveals a tumor that abuts or invades the optic chiasm, brainstem, or thalamus, when the tumor volume exceeds the institutional limit for single-fraction delivery, or when histologic diagnosis is unavailable before treatment. Consultation with a veterinary neurologist is appropriate for patients with seizure activity, vestibular signs, or suspected increased intracranial pressure, as these conditions may require medical management before anesthesia and imaging.

Laboratory involvement is required for histopathologic confirmation of tumor type when biopsy is feasible. The American College of Veterinary Radiology provides resources on specialty standards and imaging practice that can guide referral decisions. General practice resources from the American Veterinary Medical Association address professional standards for imaging and treatment documentation. Regulatory reporting obligations vary by jurisdiction, and clinicians should consult their local veterinary licensing body when a complication results in patient death or serious injury.

Troubleshooting Table

Frequently Asked Questions

How Much Does CT-Guided Stereotactic Radiosurgery Planning Cost, and What Factors Drive the Price?

Costs vary substantially by region and facility. The planning phase includes the CT simulation session, anesthesia, image fusion with MRI when available, contouring time, and physics quality assurance. Linear accelerator-based systems require specialized software and hardware that carry significant capital and maintenance costs. Referral centers typically bundle planning and treatment into a single estimate. The number of tumors, need for repeat imaging, and complexity of target delineation influence the final figure. Ask the treating facility for an itemized estimate before committing. Some academic institutions offer reduced fees for clinical research cases, and American College of Veterinary Radiology resources can help identify specialty practices in your region.

What Can I Do When a Dedicated Stereotactic Headframe or Frameless System Is Unavailable?

Fractionated radiation therapy remains a reasonable alternative when radiosurgery equipment is not accessible. Standard CT-based planning with a thermoplastic mask and three-dimensional conformal techniques can deliver multiple smaller fractions over several weeks. This approach sacrifices the steep dose gradients and single-session convenience of radiosurgery but is widely available. If you are considering referral, confirm whether the receiving facility offers dedicated stereotactic capabilities before recommending the procedure. The original veterinary radiosurgery descriptions used a stereotactic headframe secured to the skull with CT-based localizer coordinates, and the institutional report on stereotactic headframe radiosurgery in dogs documents that approach. For practices without any radiation oncology service, early referral to a specialty center is preferable to delayed treatment.

How Should I Document the Planning Process in the Medical Record?

Record the CT acquisition parameters, including slice thickness, field of view, and contrast administration. Document which images were fused, the fusion method, and the person who performed the registration. List all contoured volumes with their definitions, the prescribed dose, and the dose constraints applied to critical structures. Note any plan modifications and the rationale. Include the quality assurance checks performed before treatment delivery. The American Veterinary Medical Association practice resources provide general medical record standards that apply to radiation oncology documentation. Retain all imaging studies and planning data in accordance with local record retention requirements, as these files may be needed for future comparison or medicolegal review.

How Do I Explain the Planning Procedure to an Owner Who Is Anxious About the CT Scan Itself?

Owners often worry that the planning CT is itself a treatment or that it will cause discomfort. Explain that the scan is purely diagnostic and positional, lasting roughly 30 to 60 minutes under general anesthesia. Emphasize that the images create a three-dimensional map used to aim radiation precisely at the tumor while sparing normal brain. Mention that the dog will feel nothing during the scan and that anesthesia carries the same risks as any anesthetic event. The MSD Veterinary Manual professional edition provides accessible summaries of brain tumor diagnosis and treatment that can supplement your explanation. Reassure owners that the planning scan is a mandatory prerequisite, not an optional extra, and that its quality directly influences treatment accuracy.

Does the Planning Approach Differ for Cats or Other Species?

The principles of CT-based stereotactic planning transfer across species, but practical differences exist. Canine skull size and conformation vary widely by breed, which affects positioning and frame fit. Feline patients have smaller cranial volumes, requiring thinner slice collimation and smaller target margins to maintain comparable dose gradients. The evidence base for veterinary radiosurgery is dominated by canine studies, and the porcine model of small-volume stereotactic brain radiosurgery demonstrates that dose tolerance and tissue response differ by species and by white matter versus grey matter location. For exotic species or brachycephalic cats, consult a radiation oncologist early, as standard canine protocols may not apply directly.

What Follow-Up Imaging Is Expected After Radiosurgery, and Who Interprets It?

Most protocols recommend MRI or contrast-enhanced CT at three and six months post-treatment, then at six to twelve month intervals thereafter. The prospective study of perfusion and volume response in canine brain tumors after stereotactic radiosurgery documented significant tumor volume reduction by the first recheck, with blood flow and blood volume also declining. The radiation oncologist and a board-certified radiologist typically interpret follow-up studies jointly, because distinguishing residual tumor from radiation necrosis requires experience with post-radiosurgery changes. Refer the owner back to the treating facility for scheduled rechecks instead of relying on local imaging alone, as consistent technique and interpretation are essential for meaningful comparison.

Related Clinical & Scientific Guides

• MRI Monitoring of Brain Tumor Response to Therapy in Dogs
• Ultrasound-Guided Drainage of Abscesses in Small Animals
• Radiographic Monitoring of Total Hip Replacement in Dogs

References and Further Reading

• Radiosurgery using a stereotactic headframe system for irradiation of brain tumors in dogs.. 2001.
• Development of a novel animal model to differentiate radiation necrosis from tumor recurrence.. 2012.
• Perfusion and Volume Response of Canine Brain Tumors to Stereotactic Radiosurgery and Radiotherapy.. 2016.
• Radionecrosis and cellular changes in small volume stereotactic brain radiosurgery in a porcine model.. 2020.
• Brain arteriovenous malformations.. 2015.
• Radiobiology of radiosurgery: Part II. The rat C6 glioma model.. 1992.
• American College of Veterinary Radiology Resources. American College of Veterinary Radiology.
• MSD Veterinary Manual, Professional Edition. MSD Veterinary Manual.
• American Veterinary Medical Association Practice Resources. American Veterinary Medical Association.

Related Articles

• CT-Guided Radiation Therapy Planning in Veterinary Oncology
• CT-Guided Biopsy of Bone Lesions in Dogs and Cats
• CT-Guided Biopsy of Thoracic and Abdominal Lesions in Dogs and Cats
• CT-Guided Interventional Pain Management in Veterinary Practice
• MRI Monitoring of Brain Tumor Response to Therapy in Dogs

This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.